The collaboration with BeiGene could potentially increase the usage and visibility of Adaptive Biotechnologies' clonoSEQ Assay, which could have a positive impact on the company's revenues and stock price in the short term.

The collaboration with Adaptive Biotechnologies could enhance BeiGene's lymphoid malignancy pipeline by providing a more precise measurement of minimal residual disease, which could potentially improve the effectiveness of its treatments and have a positive impact on the company's stock price in the short term.